EUVIMEDEUVIMED entdecken
Crossref

Integrated multi‐omics and machine learning reveal a gefitinib resistance signature for prognosis and treatment response in lung adenocarcinoma

Dong Zhou, Zhi Zheng, Yanqi Li, Jiao Zhang, Xiao Lu, Hong Zheng iD, Jigang Dai

IUBMB Life · 2025

DOI: 10.1002/iub.2930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Dong Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China. Hauptthemen laut MEDLINE: Gefitinib, Drug Resistance, Neoplasm, Machine Learning, Adenocarcinoma of Lung. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Key Projects on Technological Innovation and Application Development of Chongqing, National Natural Science Foundation of China, Science and Technology Commission and Health Commission joint medical research program of Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gefitinib resistance (GR) presents a significant challenge in treating lung adenocarcinoma (LUAD), highlighting the need for alternative therapies. This study explores the genetic basis of GR to improve prediction, prevention, and treatment strategies. We utilized public databases to obtain GR gene sets, single‐cell data, and transcriptome data, applying univariate and multivariate regression analyses alongside machine learning to identify key genes and develop a predictive signature. The signature's performance was evaluated using survival analysis and time‐dependent ROC curves on internal and external datasets. Enrichment and tumor immune microenvironment analyses were conducted to understand the mechanistic roles of the signature genes in GR. Our analysis identified a robust 22‐gene signature with strong predictive performance across validation datasets. This signature was significantly associated with chromosomal processes, DNA replication, immune cell infiltration, and various immune scores based on enrichment and tumor microenvironment analyses. Importantly, the signature also showed potential in predicting the efficacy of immunotherapy in LUAD patients. Moreover, we identified alternative agents to gefitinib that could offer improved therapeutic outcomes for high‐risk and low‐risk patient groups, thereby guiding treatment strategies for gefitinib‐resistant patients. In conclusion, the 22‐gene signature not only predicts prognosis and immunotherapy efficacy in gefitinib‐resistant LUAD patients but also provides novel insights into non‐immunotherapy treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GefitinibDrug Resistance, NeoplasmMachine LearningAdenocarcinoma of LungLung NeoplasmsTumor MicroenvironmentGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorAntineoplastic AgentsTranscriptomeGene Expression ProfilingMultiomics

Stichwörter der Autor:innen

LUADgefitinib resistanceimmune microenvironmentimmunotherapy efficacypredictive signaturesingle‐cell sequencing

Substanzen

GefitinibBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.

ORCID-Profile: Hong Zheng

Förderung

  • Key Projects on Technological Innovation and Application Development of Chongqing
  • National Natural Science Foundation of China
  • Science and Technology Commission and Health Commission joint medical research program of Chongqing

Zitieren

APA

Zhou, D., Zheng, Z., Li, Y., Zhang, J., Lu, X., Zheng, H., & Dai, J. (2025). Integrated multi‐omics and machine learning reveal a gefitinib resistance signature for prognosis and treatment response in lung adenocarcinoma. IUBMB Life. https://doi.org/10.1002/iub.2930

Vancouver

Zhou D, Zheng Z, Li Y, Zhang J, Lu X, Zheng H, et al. Integrated multi‐omics and machine learning reveal a gefitinib resistance signature for prognosis and treatment response in lung adenocarcinoma. IUBMB Life. 2025. doi:10.1002/iub.2930

BibTeX
@article{Zhou2025,
  author = {Zhou, Dong and Zheng, Zhi and Li, Yanqi and Zhang, Jiao and Lu, Xiao and Zheng, Hong and Dai, Jigang},
  title = {Integrated multi‐omics and machine learning reveal a gefitinib resistance signature for prognosis and treatment response in lung adenocarcinoma},
  journal = {IUBMB Life},
  year = {2025},
  doi = {10.1002/iub.2930}
}
Kostenlos starten →